Ardelyx (ARDX) Payables (2013 - 2026)
Ardelyx's (ARDX) quarterly Payables came in at $28.2 million in Q1 2026, up 105.47% YoY from $13.7 million in Q1 2025, and up 46.58% on a QoQ basis from $19.2 million in Q4 2025.
Ardelyx (ARDX) Payables (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Payables data on file, last reported at $28.2 million in Q1 2026.
- Quarterly Payables rose 105.47% year-over-year to $28.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.2 million (up 105.47% YoY) and the FY2025 annual result came in at $19.2 million, up 20.22% from the prior year.
- Payables grew to $28.2 million in Q1 2026, from $19.2 million in the prior quarter.
- In the past five years, Payables ranged from a high of $28.2 million in Q1 2026 to a low of $3.1 million in Q3 2022.
- A 5-year average of $12.9 million and a median of $11.1 million in 2023 frame the typical range for Payables.
- The widest YoY moves for Payables: up 153.89% in 2022, down 26.98% in 2022.
- Tracing ARDX's Payables over 5 years: stood at $10.9 million in 2022, then climbed by 2.57% to $11.1 million in 2023, then soared by 43.65% to $16.0 million in 2024, then grew by 20.22% to $19.2 million in 2025, then soared by 46.58% to $28.2 million in 2026.
- The last three Payables figures came in at $28.2 million (Q1 2026), $19.2 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 38.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.41 Mn |
| Mar 31, 2026 | 28.20 Mn |
| Dec 31, 2025 | 19.24 Mn |
| Sep 30, 2025 | 18.39 Mn |
| Jun 30, 2025 | 21.69 Mn |
| Mar 31, 2025 | 13.72 Mn |
| Dec 31, 2024 | 16.00 Mn |
| Sep 30, 2024 | 15.82 Mn |
| Jun 30, 2024 | 10.88 Mn |
| Mar 31, 2024 | 17.28 Mn |
| Dec 31, 2023 | 11.14 Mn |
| Sep 30, 2023 | 7.74 Mn |
| Jun 30, 2023 | 5.29 Mn |
| Mar 31, 2023 | 10.51 Mn |
| Dec 31, 2022 | 10.86 Mn |
| Sep 30, 2022 | 3.11 Mn |
| Jun 30, 2022 | 4.29 Mn |
| Mar 31, 2022 | 5.03 Mn |
| Dec 31, 2021 | 4.28 Mn |
| Sep 30, 2021 | 4.26 Mn |